| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | |||||||||||||||||||||||||||
2 | PUB : Permohonan Ubat Baru Tahun 2.2025 (Ubat kuota) | ||||||||||||||||||||||||||
3 | Generic Name | MDC | Indications | Dosage | Category | Department | |||||||||||||||||||||
4 | 1 | Abacavir sulphate 300mg tablet | J05AR02-964-T10-01-XXX | Antiretroviral combination therapy of HIV infection in adults and adolescents from 12 years of age. | 600mg ON | A* | PUB: Medical (ID) | ||||||||||||||||||||
5 | 2 | Abacavir Sulphate 600mg and Lamivudine 300mg Tablet | J05AF06-183-T10-01-XXX | Antiretroviral combination therapy of HIV infection in adults and adolescents from 12 years of age with the following criteria: i)Patients unsuitable or failed other HAART treatment. ii)Patients who are at high risk of renal impairment. iii)Patients with osteoporosis or at high risk of bone loss. | ADULTS & ADOLESCENT (> 12 years of age): Recommended dose is one tablet once daily. Not to be used in adults or adolescents weigh less than 40kg. CHILDREN : Not recommended | A* | PUB: Medical (ID) | ||||||||||||||||||||
6 | 3 | Abiraterone 250mg Tablet | L02BX03-000-T10-01-001) | With prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men. Prescribing restriction: i. Those who have progressed on OR failed prior docetaxel chemotherapy ii. Those who are contraindicated or unsuitable for chemotherapy | 1,000mg once daily | A* | PUB: Urology | ||||||||||||||||||||
7 | 4 | Acetazolamide 250 mg Tablet | S01EC01000T1001XX | Reduction of intraocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucoma | 250 - 500 mg daily | B | |||||||||||||||||||||
8 | 5 | Acetazolamide 500 mg Injection | S01EC01000P4001XX | Reduction of intra-ocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucoma | 250 - 500 mg given by IM or IV | B | |||||||||||||||||||||
9 | 6 | Acetylcysteine 200 mg/ml Injection | V03AB23520P3001XX | i. Antidote for paracetamol poisoning ii. UKK indication : Please refer UKK folder | i. Diluted with dextrose 5% and infused IV. Initial, 150 mg/kg IV in 200 ml over 60 minutes, then 50 mg/kg IV in 500 ml over 4 hours, followed by 100 mg/kg IV in 1000 ml over 16 hours. Total dose: 300mg/kg in 20 hour ii. Please refer UKK folder | A* | |||||||||||||||||||||
10 | 7 | Acetylsalicylic Acid 100 mg, Glycine 45 mg Tablet | B01AC06259T1001XX | Prevention of myocardial infarct, stroke, vascular occlusion and deep vein thrombosis. Transient ischaemic attacks | 1 tablet daily | B | |||||||||||||||||||||
11 | 8 | Acetylsalicylic Acid 300 mg Soluble Tablet | N02BA01000T4001XX | Initial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction and for the prevention of cardiovascular events in patients at risk. Other such uses include the treatment and prevention of cerebrovascular disorders such as stroke | 150mg to be taken daily. Dose to be individualised. Use in children under 16 years old is not recommended | C | |||||||||||||||||||||
12 | 9 | Acetylsalicylic Acid 150mg Dispersible Tablet | N02BA01-000-T40-03-XXX | Initial treatment of cardiovascular disorders such as angina pectoris and myocardial infarction and for the prevention of cardiovascular events in patients at risk. Other such uses include the treatment and prevention of cerebrovascular disorders such as stroke. | 150mg to be taken daily. Use in children under 16 years old is not recommended | C | |||||||||||||||||||||
13 | 10 | Acitretin 10 mg Capsule | D05BB02000C1001XX | Generalised pustular and or erythrodermic psoriasis, pityriasis rubra pilaris, Darier's Disease, Icthyosiform Erythrodermas - Bullous and non-bullous forms, extensive naevus verrucosus, extensive psoriasis | ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). CHILD: 500 mcg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods | A* | PUB : Dermatology | ||||||||||||||||||||
14 | 11 | Acitretin 25 mg Capsule | D05BB02000C1002XX | Generalised pustular and or erythrodermic psoriasis, pityriasis rubra pilaris, Darier's Disease, Icthyosiform Erythrodermas - Bullous and non-bullous forms, extensive naevus verrucosus, extensive psoriasis | ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). CHILD: 500 mcg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods | A* | PUB : Dermatology | ||||||||||||||||||||
15 | 12 | Acriflavine 0.1% Lotion | D08AA03000L6001XX | Infected skin, lesions, cuts, abrasions, wounds and burns. | Apply undiluted three times daily to the affected part . | C | |||||||||||||||||||||
16 | 13 | Acyclovir 200 mg Tablet | J05AB01000T1001XX | i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster) | i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2 years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times daily | A/KK | |||||||||||||||||||||
17 | 14 | Acyclovir 200 mg/5 ml Suspension | J05AB01000L8001XX | i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg.Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster) | i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD : less than 2 years, half adult dose; more than 2 years, adult dose. v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD: less than 2 years; 400mg 4 times daily, more than 2 years; 800 mg 4 times daily | A* | |||||||||||||||||||||
18 | 15 | Acyclovir 250 mg Injection | J05AB01000P4001XX | Treatment and prophylaxis of herpes simplex in immunocompromised, severe initial genital herpes and Varicella -Zoster | ADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to 10mg/kg every 8 hourly in varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis; possibly for 14 - 21 days). NEONATE & INFANT up to 3 months with disseminated herpes simplex: 20mg/kg every 8 hourly for 14 days (21 days in CNS involvement), varicella-zoster 10-20mg/kg every 8 hourly usually for 7 days. CHILD, 3 months - 12 years: Herpes simplex or Varicella Zoster: 250 mg/m2 8 hourly for 5 days, doubled to 500 mg/m2 8 hourly for varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for 10 days in encephalitis) | A* | |||||||||||||||||||||
19 | 16 | Acyclovir 5% Cream | D06BB03000G1001XX | Herpes simplex infections of the skin, including initial and recurrent labial and genital herpes simplex infections | Apply every 4 hours for 5 - 10 days | A* | PUB : Dermatology and Paediatric | ||||||||||||||||||||
20 | 17 | Acyclovir 800 mg Tablet | J05AB01000T1002XX | i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster) | i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2 years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times daily | A/KK | |||||||||||||||||||||
21 | 18 | Adalimumab 40 mg Injection | L04AB04000P5001XX | Third line treatment of: i) Severe rheumatoid arthritis ii) Psoriatic arthritis iii) Ankylosing spondylitis after failure of conventional DMARDs or other biologics | Subcutaneous 40 mg every other week | A* | PUB : Medical (GASTRO & RHEUMATO) | ||||||||||||||||||||
22 | 19 | Adapalene 0.1% Cream | D10AD03000G1001XX | Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoyl peroxide or topical tretinoin [third line treatment] | Apply once daily to the affected areas after washing at bedtime | A* | PUB : Dermatology | ||||||||||||||||||||
23 | 20 | Adenosine 3 mg/ml Injection | C01EB10000P3001XX | i)Rapid conversion of paroxysmal supraventricular tachycardia to sinus rhythm ii) UKK: Pharmacologic Stress Testing | ADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds). Second dose: If the first dose does not result in elimination of the supraventricular tachycardia with in 1 or 2 minutes, 6 mg should be given also as a rapid IV bolus. Third dose: If the second dose does not result in elimination of the supraventicular tachycardia with in 1-2 minutes, 12 mg should be given also as a rapid IV bolus UKK: 140 mcg/kg/min for 6 mins | B | |||||||||||||||||||||
24 | 21 | Adrenaline Acid (Epinephrine) Tartrate 1 mg/ml Injection | C01CA24123P3001XX | Cardiopulmonary resuscitation | 1 mg by intravenous injection repeated every 3-5 minutes according to response | B | |||||||||||||||||||||
25 | 22 | Agomelatine 25 mg Tablet | N06AX22-000-T10-01-XXX | Major depression | The recommended dose is 25mg once daily at bedtime, maybe increased to 50mg once daily at bedtime. | A* | PUB: Psychiatry | ||||||||||||||||||||
26 | 23 | Albendazole 200 mg Tablet | P02CA03000T1001XX | i) Single or mixed infestations of intestinal parasites ii) Strongyloides infection | i) ADULT and CHILD over 2 years : 400 mg as a single dose ii) 400 mg as a single dose for 3 consecutive days. CHILD 12 - 24 months : half adult dose | C | |||||||||||||||||||||
27 | 24 | Albendazole 200 mg/5 ml Suspension | P02CA03000L8001XX | i) Single or mixed infestations of intestinal parasites ii) Strongyloides infection | i) ADULT and CHILD over 2 years : 400 mg as a single dose ii) 400 mg as a single dose for 3 consecutive days. CHILD 12 - 24 months : half adult dose | C | |||||||||||||||||||||
28 | 25 | Alcohol 70% Solution | D08AX08000L9901XX | Use as antiseptic and disinfectant | Apply to the skin undiluted or when needed | C | |||||||||||||||||||||
29 | 26 | Alendronate 70mg tab | M05BA04-520-T10-01-XXX | FUKKM indication: Osteoporosis UKK indication: please refer UKK folder | 70 mg once weekly | A* | |||||||||||||||||||||
30 | 27 | Alendronate Sodium 70 mg and Cholecalciferol 5600 IU Tablet | M05BB03972T1002XX | Osteoporosis in post menopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk. | 1 tablet once weekly [contains cholecalciferol 2800 units in a weekly dose, equivalent to 400 units daily]. Swallow the tablet whole with a full glass of plain water only on an empty stomach at least 30 minutes before breakfast (and any other oral medication); stand or sit upright for at least 30 min and do not lie down until after eating breakfast | A* | |||||||||||||||||||||
31 | 28 | Alfacalcidol 0.25 mcg Capsule | A11CC03000C1001XX | Treatment of: i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis | Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily | A/KK | |||||||||||||||||||||
32 | 29 | Alfacalcidol 1 mcg Capsule | A11CC03000C1002XX | Treatment of: i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis | Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily | A/KK | |||||||||||||||||||||
33 | 30 | Alfacalcidol 2mcg/ml Injection | A11CC03-000-P30-01-XXX | i) Chronic kidney disease mineral bone disorder ii) Osteoporosis iii) Hypoparathyroidism and pseudohypoparathyroidism iv) Rickets and osteomalacia | Initial dose ADULT and CHILD above 20kg body weight : 1 mcg daily; CHILD under 20kg body weight : 0.05 mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is individualised based on serum calcium level and according to product insert/protocol | A* | PUB: Nephrology | ||||||||||||||||||||
34 | 31 | Alfacalcidol 2 mcg/ml Drops | A11CC03000D5001XX | Treatment of: i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis | NEONATES : 0.1 mcg/kg/day | A* | PUB : Paediatric, Nephrology | ||||||||||||||||||||
35 | 32 | Alfuzosin HCl 10 mg Tablet | G04CA01110T1001XX | Treatment of functional symptoms related with benign prostatic hypertrophy (BPH) | 10 mg once a day pre bed | A* | |||||||||||||||||||||
36 | 33 | Allopurinol 100 mg Tablet | M04AA01-000-T10-02-XXX | i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia | Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily (depending on renal function). | A/KK | PUB Medical | ||||||||||||||||||||
37 | 34 | Allopurinol 300 mg Tablet | M04AA01000T1001XX | i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia | Initial dose : 100-300 mg daily. Maintenance : 300-600 mg daily. Maximum: 900 mg daily | A/KK | |||||||||||||||||||||
38 | 35 | All-Trans Retinoic Acid (Tretinoin) 10 mg Capsule | L01XX14-000-C10-01-XXX | Acute promyelocytic leukaemia | Induction: 45 mg/m2 daily for 30 - 90 days. Maintenance: 45 mg/m2 daily for 2 weeks every 3 months. Renal/or hepatic insufficiency: 25mg/m2 daily for 30-90 days. Refer to protocols | A* | PUB: Medical (Haematology) | ||||||||||||||||||||
39 | 36 | Alprazolam 0.5 mg Tablet | N05BA12000T1002XX | Anxiety disorders | 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children | A | |||||||||||||||||||||
40 | 37 | Alprostadil 500 mcg/ml Injection | C01EA01000P3001XX | For treatment of congenital heart diseases which are ductus arteriosus dependent | 0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased to lowest effective dose | A* | |||||||||||||||||||||
41 | 38 | Alteplase 50 mg per vial Injection | B01AD02000P4001XX | i. Thrombolytic treatment of acute ischaemic stroke. Ii. UKK Indication: Right complex pleural effusion | 0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with 10% of the total dose administered as an initial intravenous bolus. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging technique. | A* | PUB: Paeds Cardiology | ||||||||||||||||||||
42 | 39 | Amantadine HCl 100 mg Capsule | N04BB01110C1001XX | i. Parkinson's disease ii. UKK indication : For disorder of consciousness in traumatic brain injury & fatigue in multiple sclerosis/post polio syndrome patients (to improve arousal) | i. Initial dose: 100 mg daily and is increased to 100 mg twice daily (not later than 4 p.m.) after a week. Elderly over 65 years: less than 100 mg or 100 mg at intervals of more than 1 day ii. 100-200 mg per day | B | |||||||||||||||||||||
43 | 40 | Amikacin 250 mg/2 ml Injection | J01GB06183P3003XX | Infections due to susceptible organisms | ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day | A | |||||||||||||||||||||
44 | 41 | Amino Acids Injection | B05BA01910P3001XX | Source of amino acids in patients needing IV nutrition | Dose to be individualised. ADULT usually 500-2000 ml by IV. ADULT usual requirement for amino acid: 1-2 g/kg/day | A | |||||||||||||||||||||
45 | 42 | Aminophylline 25 mg/ml Injection | R03DA05000P3001XX | Reversible airways obstruction, acute severe asthma | Deteriorating acute asthma not previously treated with theophylline, by slow IV injection over 20 minutes 250 - 500 mg (5 mg/kg), then as for acute severe asthma. Acute severe asthma by IV infusion : 500 mcg/kg/hour, adjusted according to plasma-theophylline concentration. CHILD : 6 month - 9 years : 1 mg/kg/hour, 10 - 16 years : 800 mcg/kg/hour | B | |||||||||||||||||||||
46 | 43 | Amiodarone 200 mg Tablet | C01BD01110T1001XX | Arrhythmias | 200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for another week. Maintenance dose, usually 200 mg daily or the minimum required to control the arrhythmia | A* | |||||||||||||||||||||
47 | 44 | Amiodarone 50 mg/ml Injection | C01BD01110P3001XX | Arrhythmias when other drugs are contraindicated or ineffective | Initial infusion of 5mg/kg via large venous access over 20-120 minutes with ECG monitoring; subsequent infusion given if necessary according to response up to a maximum of 1.2 g in 24 hours | A* | |||||||||||||||||||||
48 | 45 | Amisulpride 100 mg Tablet | N05AL05-000-T10-01-XXX | Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominate | Predominantly negative episodes: 50-300 mg once daily adjusted according to the patient?s response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient?s response. Should be taken on an empty stomach (Preferably taken before meals) | A* | PUB : Psychiatry | ||||||||||||||||||||
49 | 46 | Amisulpride 400 mg Tablet | N05AL05-000-T10-02-XXX | Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominate | Predominantly negative episodes: 50-300 mg once daily adjusted according to the patient?s response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient?s response. Should be taken on an empty stomach (Preferably taken before meals) | A* | PUB : Psychiatry | ||||||||||||||||||||
50 | 47 | Amitriptyline HCl 25 mg Tablet | N06AA09110T1001XX | Depression | Initially 75 mg. ADULT and ELDERLY : 30 - 75 mg daily in divided doses or as a single dose at bedtime, increase gradually as necessary to 150 - 200 mg. CHILD under 16 years are not recommended | B | |||||||||||||||||||||
51 | 48 | Amlodipine 10 mg and Valsartan 160 mg Tablet | C09DB01935T1003XX | Essential hypertension in patients whose blood pressure is not adequately controlled by monotherapy | Doses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg | A/KK | PUB : Cardiology, Nephrology, Medical | ||||||||||||||||||||
52 | 49 | Amlodipine 10 mg Tablet | C08CA01000T1002XX | Hypertension | 5 mg once daily. Max: 10 mg | B | |||||||||||||||||||||
53 | 50 | Amlodipine 5 mg Tablet | C08CA01000T1001XX | Hypertension | 5 mg once daily. Max: 10 mg | B | |||||||||||||||||||||
54 | 51 | Amlodipine 5 mg and Valsartan 160 mg Tablet | C09DB01935T1002XX | Essential hypertension in patients whose blood pressure is not adequately controlled by monotherapy | Doses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg | A/KK | PUB : Cardiology, Nephrology, Medical | ||||||||||||||||||||
55 | 52 | Amorolfine 5% Nail Lacquer | D01AE16-110-L50-01-XXX | Fungal nail infections | Apply to affected nail once or sometimes twice a week after filling and cleansing, allow to dry, treat finger nail for 6 months, toe nail for 9 - 12 months (review at intervals of 3 months) | A* | PUB: Dermatology | ||||||||||||||||||||
56 | 53 | Amoxicillin & Clavulanate 228 mg/5 ml Syrup | J01CR02961F2102XX | Infections caused by susceptible organisms | Moderate infections: CHILD 7 - 12 year: 10 ml, 2 - 6 year: 5 ml. Severe infections: 2 - 6 year: 10 ml | A/KK | |||||||||||||||||||||
57 | 54 | Amoxicillin 1 g & Clavulanate 200 mg Injection | J01CR02961P4002XX | Infections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitis | CHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly | A | |||||||||||||||||||||
58 | 55 | Amoxicillin 250 mg Capsule | J01CA04012C1001XX | Infections caused by susceptible strains of gram positive and gram negative organisms | ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly | B | |||||||||||||||||||||
59 | 56 | Amoxicillin 500 mg & Clavulanate 125 mg Tablet | J01CR02961T1002XX | Infections due to beta-lactamase producing strain where amoxicillin alone is not appropriate. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitis | ADULT & CHILD more than 12 years: Mild to moderate infections: 625 mg twice daily. Severe infections: 1 g twice daily | A/KK | |||||||||||||||||||||
60 | 57 | Amoxicillin Trihydrate 125 mg/5 ml Syrup | J01CA04012F1001XX | Infections caused by susceptible strains of gram positive and gram negative organisms | CHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses | B | |||||||||||||||||||||
61 | 58 | Amphotericin B 50 mg Injection (CONVENTIONAL) | J02AA01801P4001XX | Systemic fungal infections | ADULT: 0.25 mg/kg/day by IV infusion, gradually increase if tolerated to 1 mg/kg/day. Maximum in severe cases: 1.5 mg/kg daily or on alternate days. For neonates, lower doses are recommended | A | |||||||||||||||||||||
62 | 59 | Ampicillin Sodium & Sulbactam Sodium 375 mg Tablet | J01CR01961T1001XX | Treatment of susceptible bacterial infections | ADULT & CHILD more than 30 kg: 375 - 750 mg twice daily. Maximum: 3 g daily | A/KK | |||||||||||||||||||||
63 | 60 | Ampicillin Sodium 1g & Sulbactam Sodium 500mg Injection | J01CR01961P4002XX | Treatment of susceptible bacterial infections | ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of surgical infections: 1.5 - 3 g at induction of anaesthesia. May be repeated 6 - 8 hourly. NEONATES: First week of life, 75mg/kg/day in divided doses every 12 hour | A | |||||||||||||||||||||
64 | 61 | Ampicillin Sodium 500 mg Injection | J01CA01520P4001XX | Treatment of susceptible bacterial infections (non beta-lactamase-producing organisms); meningitis | 250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 mg/kg/day. Meningitis: 2 g 6 hourly. CHILD: 150 mg/kg/daily IV in divided doses. Usual children dose less than 10 years, half adult dose | B | |||||||||||||||||||||
65 | 62 | Anti RhD Gamma Globulin 300 mcg/2 ml Injection (500 units=100 mcg) | J06BB01000P3001XX | Prevention of Rh(D) sensitisation by IM injection to rhesus-negative woman after delivery of rhesus-positive infant | 50 - 100 mcg within 72 hours after incompatible blood transfusion: 25 mcg (125 units) per ml transfused blood, up to 1000 mcg | B | |||||||||||||||||||||
66 | 63 | Antivenene Malaysian Pit Viper Injection | J06AA03000P3001XX | Bitten by pit viper | Reconstitute content for the vial with 5 ml sterile pyrogen-free distilled water. Administer by IV infusion 200 ml of normal saline over a period of 1 - 2 hours | B | |||||||||||||||||||||
67 | 64 | Antivenene Serum Snake (Neuro Polyvalent Inj) | J06AA03-000-P30-03-XXX | Malayan Krait Snake Bite with Envenomation Neurotoxicity | 5 vials/cycle for 2 cycles | B | |||||||||||||||||||||
68 | 65 | Antivenene Serum Snake (Hemato Polyvalent Inj) | J06AA03-000-P30-03-XXX | Moderate to severe envenomation caused by hematotoxic snake | 3 vials/cycle for 1 cycle | B | |||||||||||||||||||||
69 | 66 | Antivenene Serum (Cobra) Injection | J06AA03000P3002XX | Treatment for cobra bites | The reconstituted antivenin should be given by slow intravenous infusion, approximately 2ml/min.Subsequent dose can be given every 12 hours according to the clinical symptoms | B | |||||||||||||||||||||
70 | 67 | Apixaban 2.5mg film coated tablet. | B01AF02000T3201XX | Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Restriction: Only for renal patients. | 5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally twice daily in NVAF patients with at least two of the following characteristics: age ≥80 years old, body weight≤60kg, or serum creatinine≥1.5mg/dL (133micromole/L). | A* | PUB: Cardiology, Nephrology | ||||||||||||||||||||
71 | 68 | Apixaban 5mg film coated tablet. | B01AF02000T3202XX | Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Restriction: Only for renal patients. | 5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally twice daily in NVAF patients with at least two of the following characteristics: age ≥80 years old, body weight≤60kg, or serum creatinine≥1.5mg/dL (133micromole/L). | A* | PUB: Cardiology, Medical,Nephrology | ||||||||||||||||||||
72 | 69 | Aqueous Cream | D02AX00000G1001XX | Dry skin | As a soap or apply to the skin as an emollient cream | C | |||||||||||||||||||||
73 | 70 | Aripiprazole 10mg Tablet | N05AX12000T1001XX | i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorder | Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour | A* | PUB : Psychiatry | ||||||||||||||||||||
74 | 71 | Aripiprazole 15mg Tablet | N05AX12000T1002XX | i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorder | Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour | A* | PUB : Psychiatry | ||||||||||||||||||||
75 | 72 | Artemether 20mg + Lumefantrine 120mg | P01BE52981T1001XX | Acute uncomplicated falciparum malaria | ADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as a single dose at the time of initial diagnosis, again 4 tablets after 8 hours and then 4 tablets twice daily (morning and evening) on each of the following two days (total course comprises 24 tablets). INFANT and CHILD weighing 5 kg to less than 35 kg : A 6 dose regimen with 1 to 3 tablets per dose, depending on bodyweight | B | PUB : Medical | ||||||||||||||||||||
76 | 73 | Asenapine 10mg Sublingual Tablet | N05AH05253T7002XX | For second or third line treatment in adult for: i) Schizophrenia ii) Bipolar Disorder - Monotherapy: Acute treatment of manic or mixed episodes associated with Bipolar I disorder. - Adjunctive therapy: As adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with Bipolar I Disorder. | i) Schizophrenia: - Acute treatment in adults: Recommended starting and target dose of asenapine is 5mg given twice daily. - Maintenance dose: 5mg twice daily. ii) Bipolar Disorder: - Monotherapy: 10mg twice daily. Adjunctive therapy: 5mg twice daily with lithium or valproate. Dose can be increased to 10mg twice daily based on clinical response. | A* | PUB: Psychiatry | ||||||||||||||||||||
77 | 74 | Artesunate 60 mg Injection | P01BE03000P3001XX | Treatment of severe malaria caused by Plasmodium falciparum in adults and children | 2.4mg of artesunate/kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted. For adults and children with severe malaria or who are unable to tolerate oral medicines, artesunate 2.4 mg/kg body weight IV or IM given on admission (time = 0), then at 12 hrs and 24 hrs, then once a day for 5-7 days is the recommended treatment. | A | |||||||||||||||||||||
78 | 75 | Ascorbic Acid 100 mg Tablet | A11GA01000T1002XX | Vitamin C deficiency | ADULT: 100-250 mg once or twice daily CHILD: 100 mg three times daily for one week followed by 100mg daily until symptoms abate. | C | |||||||||||||||||||||
79 | 76 | Atazanavir 300mg capsule | J05AE08-183-C11-01-XXX | Treatment of HIV-1 infected, antiretroviral treatment experienced adults, in combination with other antiretroviral medicinal products. | The recommended dose is 300mg once daily taken with ritonavir 100mg once daily and with food. Ritonavir is used as a booster of atazanavir pharmacokinetics. If atazanavir with ritonavir is co- administrated with didanosine, it is recommended that didanosine be taken 2 hours after atazanavir with ritonavir taken with food. | A* | PUB: Medical | ||||||||||||||||||||
80 | 77 | Atorvastatin 20 mg Tablet | C10AA05000T1002XX | Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy | 10 mg once daily. Maximum: 80 mg daily | A* | |||||||||||||||||||||
81 | 78 | Atorvastatin 40 mg Tablet | C10AA05000T1001XX | Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy | 10 mg once daily. Maximum: 80 mg daily | A* | |||||||||||||||||||||
82 | 79 | Atorvastatin 80 mg Tablet | C10AA05000T1004XX | Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy | 10 mg once daily. Maximum: 80 mg daily | A* | |||||||||||||||||||||
83 | 80 | Atracurium Besylate 25 mg/2.5 ml Injection | M03AC04197P3001XX | Muscle relaxation | ADULT and CHILD more than 1 month: Initially 300 - 600 mcg/kg IV injection. Subsequent doses of 80 - 200 mcg/kg may be given as necessary. IV infusion: 5 - 10 mcg/kg/minute (300 - 600 mcg/kg/hour) | A* | |||||||||||||||||||||
84 | 81 | Atropine Sulphate 1% Eye Drops | S01FA01183D2001XX | Determination of refraction, strabismus, iritis and iridocyclitis, after extra or intracapsular extraction of lens | PREOPERATIVE MYDRIASIS : one drop of a 1% solution supplemented with one drop of 2.5 or 10% phenylephrine prior to surgery. ANTERIOR UVEITIS or POSTOPERATIVE MYDRIASIS : one drop of a 1% or 2% solution up to 3 times a day | B | |||||||||||||||||||||
85 | 82 | Atropine Sulphate 1mg/ml Injection | A03BA01183P3001XX | i) Reduce vagal inhibition,salivary and bronchiol secretion in anaesthesia ii) Reversal of excessive bradycardia iii) Reversal of effect of competitive muscle relaxants iv) Overdosage with other compounds having muscarinic action v) Organophosphate poisoning | i) ADULT 300-600 mcg IM/SC 30-60 minutes before anaesthesia or 300-600 mcg IV immediately before induction of anaesthesia ii) ADULT 0.5-1 mg repeated, every 3-5 minutes. Max Dosage: 0.04 mg/kg body weight iii) ADULT 0.6-1.2 mg before or with anticholinesterase iv) ADULT 0.5-1 mg IV/SC, repeated every 2 hour v) ADULT 2 mg IV/IM, every 30 minutes according to clinical response. Cholinesterase reactivator should be given at the earliest possible time | B | |||||||||||||||||||||
86 | 83 | Azathioprine 50 mg Tablet | L04AX01000T1001XX | i)Acute leukaemia ii)Immunosuppressive agent iii) UKK Indication: CTD-ILD | i) 1-4 mg/kg/day ii) 1.5-2 mg/kg/day | A | |||||||||||||||||||||
87 | 84 | Azelastine Hydrochloride 137mcg & Fluticasone Propionate 50mcg Nasal Spray | R01AD58-984-A41-01-XXX | Symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate | One actuation in each nostril twice daily | A* | PUB: ENT | ||||||||||||||||||||
88 | 85 | Azelaic Acid 20% Cream | D10AX03-000-G10-01-XXX | Acne vulgaris | Apply twice daily (sensitive skin, once daily for 1st week). Treatment should not exceed 6 months | A* | PUB : Derm | ||||||||||||||||||||
89 | 86 | Azithromycin 200 mg/5 ml Granules | J01FA10011F1001XX | Treatment of complicated respiratory tract infections not responding to standard macrolides | CHILD 36 - 45 kg: 400 mg, 26 - 35 kg: 300mg, 15 - 25 kg 200 mg, less than 15 kg: 10 mg/kg. To be taken daily for 3 days or to be taken as a single dose on day 1, then half the daily dose on days 2 - 5 | A* | |||||||||||||||||||||
90 | 87 | Azithromycin 250 mg Tablet | J01FA10011T1001XX | i) Treatment of complicated respiratory tract infection not responding to standard macrolides ii) Adult treatment of uncomplicated genital infections due to Chlamydia trichomatis or susceptible Neisseria gonorrhoea iii) Prophylaxis against Mycobacterium avium complex in patients with advanced HIV | i) 500 mg daily for 3 days ii) 1 g as a single dose iii) 1 g weekly | A* | |||||||||||||||||||||
91 | 88 | Azithromycin 500 mg Injection | J01FA10011P4001XX | Only for treatment of severe atypical pneumonia | 500 mg IV as a single daily dose for a minimum of two days followed by 500 mg oral dose as a single daily dose to complete a 7 - 10 days course | A* | |||||||||||||||||||||
92 | 89 | Bacillus Calmete-Guerin 80mg Intravesical | L03AX03-000-P30-01-XXX | Bladder cancer | Administered in either an induction (once weekly for 6 weeks) or maintenance (once weekly for 3 weeks) course. Another 6 week course may be administered if a repeat cytoscopy reveals tumor persistence or recurrence. Induction therapy combined with maintenance therapy every 3-6 months for 1-3 years | UKK | |||||||||||||||||||||
93 | 90 | Baclofen 10 mg Tablet | M03BX01000T1001XX | Spasticity of the skeletal muscle | ADULT: 5 mg 3 times daily. Max: 80 mg daily. CHILD: 0.75 - 2 mg/kg daily (more than 10 years, maximum: 2.5 mg/kg daily) | B | |||||||||||||||||||||
94 | 91 | Baricitinib 4mg film-coated tablets | L04AA37-000-T32-02-XXX | 1. Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. May be used as monotherapy or in combination with methotrexate. 2. Indicated for the treatment of severe atopic dermatitis in adult patients who are candidates for systemic therapy. | 4mg OD | A* | PUB: Medical (Rheumatology), Dermatology | ||||||||||||||||||||
95 | 92 | BCG Vaccine Freeze-Dried Injection | J07AN01000P4001XX | For the prevention of tuberculosis | 0.1 ml by intradermal injection. INFANT under 12 months: 0.05 ml | C | |||||||||||||||||||||
96 | 93 | Beclomethasone Dipropionate 100 mcg/dose Inhalation | R03BA01133A2101XX | Prophylaxis of asthma especially if not fully controlled by bronchodilators | ADULT : 100 mcg 3 - 4 times daily or 200 mcg twice daily. CHILD more than 6 years : 50 - 100 mcg 2 - 4 times daily | B | |||||||||||||||||||||
97 | 94 | Beclomethasone dipropionate 100mcg and formoterol fumarate dehydrate 6mcg pressurized inhalation solution | R03AK07986A2101XX | Regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2 agonist) is appropriate in: i.Patients not adequately controlled with inhaled corticosteroids and ?as needed? inhaled short-acting beta2 agonist or ii.Patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists | Dose recommended for patients 18 years and above. One or two inhalations twice daily. The maximum daily dose is 4 inhalations daily. No need to adjust dose in elderly patients. There are no data available for use in patients with hepatic or renal impairment. | A/KK | PUB: Pulmonology | ||||||||||||||||||||
98 | 95 | Benralizumab 30mg Solution for Injection in Pre-filled Pen | R03DX10-000-P50-01-xxx | Benralizumab is indicated as an add-on maintenance treatment in adult patients from 18 years with severe eosinophilic asthma characterised by the following criteria: a) At least two exacerbations in the past 12 months on the current standard therapy (high-dose inhaled corticosteroids plus long-acting bronchodilators) and/or need for treatment with systemic corticosteroids. b) Eosinophil count in the blood of ≥0.3 G/L (corresponding to ≥300 cells/μL). | 30 mg of benralizumab every 4 weeks for the first 3 doses, and then every 8 weeks thereafter administered as subcutaneous injection | A* | PUB: Pulmonology | ||||||||||||||||||||
99 | 96 | Benzathine Penicillin 2.4 mega units Injection (1.8 g) | J01CE08702P4001XX | i) Treatment of mild to moderately severe infections due to Penicillin G-sensitive organisms ii) Treatment of syphillis | i) ADULT: 1.2 mega units IM ii) For syphillis: 2.4 mega units weekly for 1 - 3 weeks | B | |||||||||||||||||||||
100 | 97 | Benzhexol 2 mg Tablet | N04AA01110T1001XX | i) Parkinson's disease ii) Drug induced parkinsonism iii) Dystonias | ADULT: Initially 1 mg daily. Maintenance: 5 - 15 mg daily in 3 - 4 divided doses. CHILD: 0.02 mg/kg/dose 8 hourly, gradually increasing to 0.1 - 0.3 mg/kg/dose | B |